Systematic review compares efficacy and safety of GLP-1 receptor agonists and SGLT2 inhibitors for Alzheimer’s disease in type 2 diabetes, suggesting implications for treatment options.
To compare the efficacy and long term safety of Glucagon-like peptide-1 receptor agonists (GLP-1RAs) to sodium-glucose cotransporter-2 inhibitors (SGLT-2i) in reducing Alzheimer’s and related dementia (ADRD) in patients with Type 2 Diabetes.
No takes yet. Share an insight, caveat, or question.
Teli et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: